Sepsis, the acute inflammation party thrown by an infection nobody wanted to attend, remains a leading cause of childhood mortality, killing roughly 3 million children under the age of five every year. That's a statistic that should ruin your day, and it's one Efferon is trying to make obsolete.

The startup, selected as one of TechCrunch Disrupt 2026's Startup Battlefield 200, has developed a medical device that it says lowers organ failure rates and significantly accelerates recovery in children. Because when antibiotics can't stop the immune system from overreacting, someone has to filter the blood and remove the deadly toxins. That someone, apparently, is Efferon.

Dima Romashin, the company's co-founder and CEO, compares sepsis to a fire. "In a fire, there are two things: the flame itself and smoke that it produces," he told TechCrunch. In sepsis, endotoxins are the flames and cytokines are the smoke. Efferon, unlike other devices on the market, has developed a mechanism that can absorb both at once. So it's a two-for-one deal on saving lives, which is a bargain in any economy.

While Efferon makes absorbers for adults, Efferon NEO, its pediatric device, is proving especially effective. Children have a significantly lower circulating blood volume, meaning they need devices engineered specifically for their physiology. Groundbreaking concept: smaller humans require smaller equipment.

In April, Efferon NEO received a CE mark, Europe's equivalent to FDA approval, making it the first multimodal blood purification device specifically engineered for pediatric sepsis. It's already used in intensive care units across 30 countries, including European hospitals, Saudi Arabia, and Thailand. The company is now preparing to file for FDA approval and is on track to hit $2 million in annualized revenue by the end of 2026.

The technology was originally developed by scientists at Moscow State University, including co-founder Ivan Bessonov. Romashin, a serial entrepreneur, stepped in earlier this year as CEO to help commercialize it. He admits Efferon isn't growing at the breakneck pace of today's AI startups, but true success is measured by something else entirely: every child who gets to go home.